Your SlideShare is downloading. ×
0
CambridgeSoft -- Virtualized Pharma in 2020
CambridgeSoft -- Virtualized Pharma in 2020
CambridgeSoft -- Virtualized Pharma in 2020
CambridgeSoft -- Virtualized Pharma in 2020
CambridgeSoft -- Virtualized Pharma in 2020
CambridgeSoft -- Virtualized Pharma in 2020
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

CambridgeSoft -- Virtualized Pharma in 2020

651

Published on

The Pistoia Alliance Conference in April 2011 included a series of 10-minute "lightning talks" from vendors about what they think pharma will look like in 2020. This presentation was delivered by John …

The Pistoia Alliance Conference in April 2011 included a series of 10-minute "lightning talks" from vendors about what they think pharma will look like in 2020. This presentation was delivered by John P. McAlister of CambridgeSoft.

Published in: Technology, News & Politics
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
651
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
18
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Pistoia Alliance – Virtualized Pharma in 2020<br />April 2011John P. McAlister<br />
  • 2. Industry in Throes of Change<br /><ul><li>Industry business strategies revisited
  • 3. Cost control is increasingly a decision driver
  • 4. Strategy is in flux at large pharma players
  • 5. Focus on sales and marketing or continue strong investment in R&D?
  • 6. Network research activities with other pharmas and cross-license IP?
  • 7. Invest in “centers of excellence” (internal or external) or traditional model?
  • 8. Benefits of small, entrepreneurial research environment
  • 9. Industry consolidation, reorganization
  • 10. Industry players, customers & suppliers consolidate and divest
  • 11. Global operations optimized – strategic diversification
  • 12. Based on markets, costs, resources
  • 13. Rapid Innovation (science and technology)
  • 14. ‘Omics, diagnostics/patient segregation, new therapeutic strategies
  • 15. Translational medicine reduced to practice</li></li></ul><li>Information Systems – Enabling Strategic Options<br /><ul><li>Capture and manage all aspects of research information from the enterprise?
  • 16. Globally distributed systems will be the norm – likely cloud-based
  • 17. Industry will require fine control of access to system and content
  • 18. Traditional “discipline-focused” systems area insufficient
  • 19. Link to medical systems to access outcomes information directly
  • 20. New procedures will be required to protect patient information
  • 21. Assume that each subject will have full genomic information available along with relevant proteome and metabolome
  • 22. Capture post-market information to assess and fine-tune product
  • 23. Incorporate analytical methods that include inference engines, hypothesis generation and analysis platforms
  • 24. Models are too simplistic for the current range of diseases
  • 25. Multidimensional parameter spaces demand novel methods for analysis and interpretation</li></li></ul><li>Research Information Systems<br />Replace paper-based workflows with detailed e-workflows across the full range of life science business areas<br />Apply decision support methods to support research<br />Market<br />Surveillance<br />Medical<br />Outcomes<br />Chemistry<br />Biology<br />‘Omic Info<br />Searchable DB<br />Strategic Decisions<br />
  • 26. Information Systems – The Future<br /><ul><li>No single supplier will provide all information systems required by research enterprise
  • 27. Specialty-based systems are already available across the disciplines
  • 28. Consolidation of closely related suppliers is inevitable, generating powerful large players
  • 29. Innovative small startups will quickly be targeted for acquisition
  • 30. Systems implementation will be a major component of the enterprise
  • 31. Cross-functional team expertise will be the gold-standard of the future
  • 32. Standards-based APIs are essential
  • 33. Collaborative relationships among major informatics suppliers will be essential for pharmaresearch and development information systems delivery</li></li></ul><li>

×